Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AR19 (amphetamine sulfate)
- Development stage
- Approved
- Lead developer
- Azurity Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intranasal, Intravenous, Inhalation
01
Overview
AR19 is an investigational immediate-release, amphetamine sulfate capsule specifically designed to resist physical manipulation for nonmedical misuse or abuse. It contains the same active ingredient as Arbor Pharmaceuticals' approved ADHD treatment Evekeo. The formulation is intended to deter misuse and abuse via non-oral administration methods such as intranasal, intravenous, and smoking routes. AR19 is formulated as pellets in a capsule with physical and chemical barriers to resist manipulation.
02
Targets
DAT (Dopamine plasma membrane transport protein)MAOA (Monoamine oxidase A)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)TAAR1 (Trace amine-associated receptor 1)
Beyond the preview
Go deeper on AR19 (amphetamine sulfate).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AR19 (amphetamine sulfate).